Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

4.650 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 23Andme Holding Co.

< Previous 1 2 3 4 5 6 7 8 9 Next >
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
Built upon peer-reviewed published science, the Historical Matches feature weaves customers’ ancestral connections into the story of human history and migration 
From 23andMe, Inc.
Via GlobeNewswire
A Few Years From Now, You'll Probably Wish You'd Followed Billionaire Investors Into This Stock
Nu Holdings went from an idea to a $50 billion business over a handful of years. Several billionaire investors are betting on even more upside. 
Via The Motley Fool
Looking Into 23andMe Holding's Recent Short Interest
Via Benzinga
Is 23andMe Stock a Smart Buy Right Now?
It's having trouble getting its core business model to work. 
Via The Motley Fool
Recap: 23andMe Holding Q3 Earnings
Via Benzinga
23andMe Launches New Genetic Reports on Common Forms of Cancer
23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by 23andMe 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new... 
From 23andMe, Inc.
Via GlobeNewswire
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of Intuitive Machines, Inc. (NASDAQ: LUNR) fell sharply in today’s pre-market trading. Intuitive Machines revealed Friday that its lunar lander, Odysseus, encountered a mishap during a touchdown... 
Via Benzinga
Earnings Scheduled For February 7, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
A Preview Of 23andMe Holding's Earnings
Via Benzinga
Former YouTube CEO's Teenaged Son Found Dead At UC Berkeley
The 19-year-old's grandmother, Esther Wojcicki, known as the "Godmother of Silicon Valley," says his death was likely a drug overdose. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Crude Oil Gains 3%; Kellanova Posts Upbeat Results
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 30 points on Thursday. The Dow traded down 0.01% to 38,675.29 while the NASDAQ rose 0.19% to 15,787.09. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Dow Tumbles Over 100 Points; US Initial Jobless Claims Fall Last Week
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.29% to 38,565.98 while the NASDAQ rose 0.26% to 15,796.91. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
23andMe Reports Third Quarter Fiscal 2024 Financial Results
Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473 
From 23andMe, Inc.
Via GlobeNewswire
Why Is Invitae (NVTA) Stock Down 75% Today?
Although genetic testing specialist Invitae forwarded a compelling idea, the lack of business substance ultimately cratered NVTA stock. 
Via InvestorPlace
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
Invitae's financial challenges as it grapples with a $1.5 billion debt burden. Explore the company's strategic options amidst potential bankruptcy, asset shedding, and cost-cutting measures. 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Troubled Biotech Company's Investigational Cancer Drug Gets Greenlighted By FDA
This development marks a significant milestone for 23andMe, a company that has been in the spotlight for security breaches in the past. 
Via Benzinga
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Faces Class Action Lawsuit Over Alleged Privacy Breach Targeting Chinese And Ashkenazi Jewish Customers
23andMe faces a class-action lawsuit for a privacy breach affecting 7 million customers, particularly Chinese and Ashkenazi Jewish customers. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
23andMe to Report FY2024 Third Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
The 3 Worst Stock Investments I Ever Made -- and What I Learned From Them
Not all of my investments have been winners. Here are three that went badly and the important lessons I learned from them. 
Via The Motley Fool
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
From 23andMe, Inc.
Via GlobeNewswire
23andMe Reveals Hackers Accessed 'Significant Number' Of DNA Records
23andMe confirmed that hackers accessed around 14,000 customer accounts and an undisclosed number of files containing users' ancestry data. 
Via Benzinga
Topics Hacking
Exposures Information Security
The 3 Best Digital Health Stocks for Personalized Medicine
Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.